MARKET

AMLX

AMLX

Amylyx Pharmaceuticals
NASDAQ
29.85
+0.36
+1.22%
After Hours: 29.85 0 0.00% 19:30 09/28 EDT
OPEN
29.10
PREV CLOSE
29.49
HIGH
30.14
LOW
28.71
VOLUME
1.02M
TURNOVER
--
52 WEEK HIGH
41.14
52 WEEK LOW
10.83
MARKET CAP
3.74B
P/E (TTM)
-20.8406
1D
5D
1M
3M
1Y
5Y
1D
Our Pick Of The Best Growth Stocks In September 2026
Simply Wall St · 3d ago
Weekly Report: what happened at AMLX last week (0914-0918)?
Weekly Report · 09/21 09:02
Is Long Term Avexitide Supply Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)?
Simply Wall St · 09/19 07:26
Amylyx Pharmaceuticals (AMLX) Signs Avexitide Supply Deals, Is The Stock Fully Priced?
Simply Wall St · 09/18 04:36
10 mid-cap healthcare stocks with the strongest momentum grades
Seeking Alpha · 09/17 14:10
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
Seeking Alpha · 09/17 13:45
Have Amylyx Pharmaceuticals Insiders Been Selling Stock?
Simply Wall St · 09/16 10:30
Weekly Report: what happened at AMLX last week (0907-0911)?
Weekly Report · 09/14 09:02
More
About AMLX
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on four investigational therapies across several diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome, AMX0114 in amyotrophic lateral sclerosis (ALS), and AMX0318 in PBH and other rare diseases. AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide and AMX0318 is a novel GLP-1 receptor antagonist.

Webull offers Amylyx Pharmaceuticals Inc stock information, including NASDAQ: AMLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMLX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMLX stock methods without spending real money on the virtual paper trading platform.